Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders

Running, not enrolling · Phase 2

Conditions studied: Myelodysplastic Syndrome, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Myelodysplastic/Myeloproliferative Overlapping Syndrome

In brief

This study will evaluate whether a geriatric assessment can lead to better treatment outcomes in older patients (age 60+) with a myeloid malignancy including acute myeloid leukemia, ,myelodysplastic syndromes, myeloproliferative neoplasms, or related blood disorders who are going to receive chemotherapy or another treatment to prepare the body for an allogeneic hematopoietic stem cell transplant (allo-HCT). The geriatric assessment includes looking at patients' cognitive function (thinking processes), physical function, mobility (ability to move the body), mood, nutrition, and current medications to help decide the type of treatment they'll receive. Another purpose of this study is to see whether use of the geriatric assessment improves participants' quality of life. We will evaluate participants' quality of life through questionnaires.

Key facts

Study ID

NCT04761770

Run by

Memorial Sloan Kettering Cancer Center

People needed

33

Starts

2021-02-15

Expected to finish

2027-02-01

Last updated by the study team

2026-02-17

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• are 60 years or older
• have a pathologically confirmed myeloid malignancies including acute myeloid leukemia, ,myelodysplastic syndrome, myeloproliferative neoplasms, or related blood disorders including chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, and myelodysplastic/myeloproliferative overlapping syndrome
• have <10% blasts in bone marrow prior to transplant
• have a matched related or unrelated donor, mismatched unrelated donor, or haploidentical donor
• Meet institutional standard criteria for allogeneic transplantation as determined by the primary transplant physician
• Undergoes transplantation using the allocated conditioning regimen intensity defined by the protocol-specified criteria below:
• HCT-CI/Age <5 and IADL normal = myeloablative regimen
• HCT-CI/Age ≥5 and/or IADL impairment = RIC/NMA regimen

You may not qualify if…

• Prior hematopoietic cell transplantation
• Cord blood donors
• Persons with active, refractory disease defined by ≥10% blasts in bone marrow prior to transplant

Where it is running

• Memorial Sloan Kettering Basking Ridge (Consent Only) — Basking Ridge, New Jersey, United States
• Memorial Sloan Kettering Monmouth (Consent Only) — Middletown, New Jersey, United States
• Memorial Sloan Kettering Bergen (Consent Only) — Montvale, New Jersey, United States
• Memorial Sloan Kettering Commack (Consent only) — Commack, New York, United States
• Memorial Sloan Kettering Westchester (Consent Only) — Harrison, New York, United States
• Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York, United States
• Memorial Sloan Kettering Nassau (Consent Only) — Uniondale, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.